<DOC>
	<DOCNO>NCT00486265</DOCNO>
	<brief_summary>The primary purpose study find maximum tolerate dose experimental drug call AZD4877 base side effect experience patient receive AZD4877 daily time 3 schedule acute myelogenous leukemia ( AML ) . For enrollment information see Central Contact information</brief_summary>
	<brief_title>Phase I/II , Open-label , Multi-center , Two Part Dose-escalation , Safety , Pharmacokinetics ( PK ) Efficacy Study AZD4877 Patients With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Part A : Relapsed refractory leukemia standard therapy anticipate result durable remission Part B : AML two prior relapse fail achieve remission least one induction treatment . Patients prior allogeneic transplant remain clinically stable â‰¥2 week immunosuppressive therapy Promyelocytic acute myelogenous leukemia Prior allogeneic transplant require immunosuppressive therapy treat physician consider patient candidate allogeneic transplantation . Liver injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>cancer</keyword>
</DOC>